United Therapeutics (UTHR) Change in Receivables (2009 - 2026)

United Therapeutics has disclosed Change in Receivables across 18 years of filings, most recently posting -$38.2 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$38.2 million, down 189.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.0 million (down 167.57% YoY), and the FY2025 annual result was $70.9 million, up 17625.0% from the prior year.
• Change in Receivables came in at -$38.2 million for Q1 2026 at United Therapeutics, down from $52.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $138.1 million in Q2 2023 to a low of -$85.9 million in Q1 2023.
• The 5-year median for Change in Receivables is $2.8 million (2022), against an average of $6.7 million.
• Across the five-year window, Change in Receivables jumped 4832.14% in 2023 and tumbled 407.88% in 2024, its largest moves.
• United Therapeutics' Change in Receivables stood at -$11.3 million in 2022, then surged by 279.65% to $20.3 million in 2023, then sank by 407.88% to -$62.5 million in 2024, then jumped by 184.0% to $52.5 million in 2025, then sank by 172.76% to -$38.2 million in 2026.
• The last three Change in Receivables figures came in at -$38.2 million (Q1 2026), $52.5 million (Q4 2025), and -$81.6 million (Q3 2025), per Business Quant data.